Search Results
Your search for ,HOW matches 8288 pages
Showing 2751 - 2800ASH Releases New Clinical Practice Guidelines on Treatment of Older Adults With Newly Diagnosed Acute Myeloid Leukemia
The American Society of Hematology (ASH) has published new guidelines to help older adults with acute myeloid leukemia (AML) and their health-care providers make critical care decisions, including if and how to proceed with cancer treatment and the need for blood transfusions for those in hospice...
Dafna Bar-Sagi, PhD, on COVID-19: How Cancer Researchers Can Help Address the Challenges
Dafna Bar-Sagi, PhD, of New York University Langone Medical Center, summarizes a panel discussion she moderated on skills the cancer research community brings to bear on the coronavirus pandemic, how the influx of funding will affect future priorities, and ways to capitalize on the surge of...
Cancer Deaths Linked to 4 Million Potential Years of Life Lost in 2017
Deaths from cancer accounted for more than 4 million potential years of life lost in 2017, according to a study published by Minkyo Song, MD, PhD, and colleagues in Cancer Epidemiology, Biomarkers & Prevention. While the cancer types with the highest death rates per capita accounted for the...
Immune-Related Adverse Events and Survival Outcomes in NSCLC
This week, we’re focusing on lung cancer—first, with a report on how therapy-related adverse events experienced by patients with lung cancer treated with immunotherapy may help to predict survival outcomes; and second, with a video about disparities in certain populations when it comes to lung...
Expert Point of View: William R. Sellers, MD
William R. Sellers, MD, Professor of Medicine at Harvard Medical School and the Dana-Farber Cancer Institute and Co-Chair of the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer, commented: “This study is a good example of how our increasing ability to study the human genome easily and in...
Mary Pasquinelli, DNP, APRN, FNP-BC, on Addressing Lung Cancer Care Equity in Vulnerable Communities
Mary Pasquinelli, DNP, APRN, FNP-BC, of the University of Illinois Hospital and Health Science System, discusses proposed U.S. Preventive Services Task Force lung cancer screening guidelines, which show race and gender disparities, and how modifying these recommendations with a risk prediction...
Expert Point of View: Therese Marie Mulvey, MD, FASCO
Therese Marie Mulvey, MD, FASCO, Director of Quality Safety and Value at the Massachusetts General Hospital North Shore Cancer Center, Boston, told The ASCO Post that this “provocative and elegant” study underscores the importance of listening to patients. “Baseline patient-reported symptoms are...
Study Finds State-Level Lung Cancer Screening Rates Not Aligned With Lung Cancer Burden in the United States
A new study published by Stacey A. Fedewa, PhD, and colleagues in JNCI: Journal of the National Cancer Institute found that state-level lung cancer screening rates were not aligned with the national lung cancer burden. The report provides the first population-based state-level screening data for...
Closing the Gap in Integrative Oncology Education
Launched in 2018 at the University of Michigan Medical School in Ann Arbor, the Integrative Oncology Scholars Program has trained 50 oncology professionals in evidence-based complementary therapies in the treatment of patients with cancer. Another 50 trainees are expected to complete the program by ...
Hospital Outpatient Payment Proposal Has Potential to Undermine Patient Access to Cancer Care
In a comment letter to the Centers for Medicare & Medicaid Services (CMS), the Association for Clinical Oncology (ASCO) expressed significant concerns that provisions in the 2021 Hospital Outpatient Prospective Payment System (HOPPS) proposed rule have the potential to undermine access to...
Your Stories: ‘Being Your Own Advocate’
Kimberly Irvine was used to taking care of the people she loved. Conquering breast cancer—twice—forced the young mom to learn how to take care of herself in a whole new way. In the Your Stories episode “Being Your Own Advocate,” she shares with fellow philanthropist Riccardo Braglia, Board Member, ...
COVID-19’s Impact on Cancer Care Around the World: Perspectives From the ASCO International Affairs Committee
As the world continues to respond to the COVID-19 pandemic, ASCO is committed to providing the most current information and resources to its members and the larger oncology community to help ensure that patients with cancer receive high-quality care. Here, members of the ASCO International Affairs...
Inaugural Class of FDA-AACR Oncology Educational Fellows Announced
The American Association for Cancer Research (AACR) has announced the 2020–2021 class of U.S. Food and Drug Administration (FDA)-AACR Oncology Educational Fellows. This is the first year of the fellowship, a joint initiative of the Oncology Center of Excellence at the FDA and the AACR. The...
My Age May Have Been a Barrier to Timely Diagnosis of Glioblastoma Multiforme
I think my age and apparent good health contributed to a delay in my diagnosis of glioblastoma multiforme. The first symptom I had of the cancer appeared on December 26, 2014, when I was 32 years old. My family and I had just gotten home from celebrating the Christmas holiday with our relatives...
Combination of Nivolumab and Ipilimumab for Unresectable Malignant Pleural Mesothelioma
On October 2, 2020, the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) was approved for first-line treatment of adult patients with unresectable malignant pleural mesothelioma.1-3 Supporting Efficacy Data Approval was based on findings in the open-label phase III CheckMate 743 trial...
Beyond BROCADE3: Just the Beginning for Veliparib-Based Therapy in Advanced BRCA-Mutated Breast Cancer
As recently reported in The Lancet Oncology and reviewed in the October 10, 2020, issue of The ASCO Post, the phase III BROCADE3 trial has shown that the addition of veliparib to carboplatin and paclitaxel improved progression-free survival in previously treated BRCA-mutated advanced breast...
Expert Point of View: Kilian M. Gust, MD
Formal discussant Kilian M. Gust, MD, of the Medical University of Austria, Vienna, reminded listeners that JAVELIN Bladder 100 was designed at a time when no checkpoint inhibitor was approved for the treatment of metastatic urothelial cancer. In the past 5 years, five immune checkpoint inhibitors...
A Doctor Shares His Rich Life in Medicine and Cancer Research
“What am I doing here? This question kept running through my mind as the incoming freshman medical students at the University of Chicago assembled for the first time.” The person asking the introspective question was Marvin Stone, fresh out of college, recently married to his wife, Jill, and now a...
Predicting Cardiovascular Disease Risk Via Routine CT Scans in Women With Breast Cancer
Coronary artery calcification scores based on routine computed tomography (CT) scans used for planning radiotherapy therapy may be able to predict which women with breast cancer have a high probability of developing cardiovascular disease. The promise of this research is that once high-risk...
Using Meaning-Centered Interventions to Address Suffering on the Cancer Journey
A large body of research has shed light on how the cancer experience and related losses often leave patients and their families struggling to find a sense of meaning in their lives.1-7 The COVID-19 pandemic has amplified these difficulties, as meaningful activities and experiences have been...
ACCC Statement on Rise of Cancer Mortality and Advanced Cancer Rates in 2020
Randall A. Oyer, MD, President of the Association of Community Cancer Centers (ACCC), released a statement regarding the rise in mortality rates of specific cancers and the rise in the occurrence of advanced metastatic cancers in 2020. New research presented at the United European Gastroenterology ...
As a Young Oncologist, Enrique Soto Pérez de Celis, MD, MSc, Met a Career-Changing Mentor at the ASCO Annual Meeting
Geriatric oncologist and researcher Enrique Soto Pérez de Celis, MD, MSc, was born in Mexico City and grew up in the nearby city of Puebla. “There were no physicians in the family who might have influenced my decision to become a doctor, but both of my parents were academics; my mother was a...
OneOncology Launches Community Oncology Research Network
OneOncology, a partnership of independent oncology practices, has announced the formation of a separate subsidiary, the OneOncology Research Network (OneR). The new platform is a national nonexclusive clinical trial site management organization that will enhance the current research programs...
Pancreatic Adenocarcinoma: Leveraging Molecular Data to Drive Clinical Advances
With the worst 5-year overall survival of all cancers and the second-leading cause of cancer death, pancreatic adenocarcinoma remains a dismal prognosis for the vast majority of patients. However, more accurate tumor staging and better understanding of distinct molecular subgroups have started to...
Committed to Excellence: Oncology Drug Development Marches on Amid a Pandemic
Instituted as part of the 21st Century Cures Act, the Oncology Center of Excellence (OCE) fosters a unified interaction between three U.S. Food and Drug Administration (FDA) centers: Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research, and Center for Devices and...
Expert Point of View: Reginald Tucker-Seeley, ScD
Formal discussant of these abstracts on financial toxicity, Reginald Tucker-Seeley, ScD, of USC Leonard Davis School of Gerontology, said the studies by Drs. Shankaran and Yabroff highlight how far the field has come in understanding the pathway from cancer diagnosis to financial hardship for...
Medical Financial Hardship: Pervasive and Possibly Linked to Mortality Among Patients With Cancer
Reducing the financial impact of cancer diagnosis and treatment may save not only bank accounts but lives as well, according to recent data. Two separate survey studies presented during the 2020 ASCO Quality Care Symposium have highlighted the pervasiveness and deadliness of financial toxicity,...
Chronic Lymphocytic Leukemia: New Treatments Achieve Deeper Remissions
At the National Comprehensive Cancer Network® (NCCN®) 2020 Virtual Congress: Hematologic Malignancies, William Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, reviewed current data on chronic lymphocytic leukemia (CLL), including promising new combinations of modern...
Fragment Analysis as a MET Exon 14 Screening Strategy in NSCLC Tumors
Comparison of two techniques used in screening non–small cell lung cancer (NSCLC) tumor samples demonstrated that fragment analysis could detect large MET exon 14 skipping deletions that were missed by next-generation sequencing, according to findings presented at the Molecular Analysis for...
Results From ASCO’s 2020 National Cancer Opinions Survey
As in past years, the results from ASCO’s 2020 National Cancer Opinions Survey showed a startling dichotomy in the perceptions of Americans on a variety of health-care issues. As expected, the two major events this year, the COVID-19 pandemic and a national reckoning over racial injustice,...
Richard Pazdur, MD, Awarded the Simon M. Shubitz Cancer Prize and Lectureship
For more than 4 decades, the University of Chicago Cancer Research Foundation’s Simon M. Shubitz Cancer Prize and Lectureship has honored an internationally renowned individual for his or her exceptional contributions to cancer research and clinical care. The recipient of this year’s award is...
Impact of COVID-19 on Well-Being in the Oncology Workforce: COVID-NOW Survey Results
The results of a survey of 1,038 doctors, nurses, pharmacists, administrators, and allied health professionals (such dietitians and physiotherapists) working in oncology in the United Kingdom’s National Health Service (NHS) during the spring wave of COVID-19 were presented by Susana N. Banerjee,...
Recently Approved and Emerging Therapies for Triple-Negative Breast Cancer
“Triple-negative breast cancer has multiple different subtypes, and there are targeted therapies that can be used based on the biomarkers that we identify for each patient,” Kari B. Wisinski, MD, noted in a review of recently approved and emerging therapies at the 2020 Lynn Sage Breast Cancer...
Cancer in Older Adults: The History of Geriatric Oncology, Part 3
In the preceding two issues of The ASCO Post, we explored the overall history of geriatric oncology from 1980 to 2020. In this concluding part of the series, we focus on the invaluable contributions made by oncology nurses to the field. Over the past several decades, geriatric oncology has...
National Academy of Medicine Elects New Members
The National Academy of Medicine recently announced the election of 90 regular members and 10 international members during its annual meeting. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated...
Fred R. Hirsch, MD, PhD, on Early-Stage Lung Cancer: Targeted Treatment and Screening
Fred R. Hirsch, MD, PhD, of The Tisch Cancer Institute at Mount Sinai, discusses lung cancer screening for aggressive early-stage lung cancer; adjuvant and neoadjuvant treatment, including the ADAURA study of EGFR-positive tumors; and how cell-free DNA analysis might be used in the future to...
Expert Point of View: Monika K. Krzyzanowska, MD
Formal discussant of the abstract, Monika K. Krzyzanowska, MD, a medical oncologist at Princess Margaret Cancer Centre and Professor of Medicine at the University of Toronto, said this study extends the evidence base on geriatric assessment in oncology and shows that geriatric assessment should be...
Study Identifies Genetic Variants Linked to Bevacizumab-Induced Adverse Events
Researchers have found two common genetic variants that may be used to predict whether patients with cancer may have severe adverse events when treated with the anti-VEGF monoclonal antibody bevacizumab. A genome-wide association study—according to researchers, the largest such study in patients...
An Integrated Framework for Improving Outcomes in Pancreatic Cancer
Drawing on several lines of ongoing research, David A. Tuveson, MD, PhD, has created a theoretical framework to consider while developing clinical trials in pancreatic cancer. In his keynote lecture at the 2020 American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer, ...
Are Neighborhood Poverty, Public Insurance Linked to Poorer Outcomes in Children With Cancer Undergoing Stem Cell Transplant?
Despite the increasing use of hematopoietic stem cell transplant as curative therapy for children with cancer and other life-threatening diseases, new research suggests that children who undergo a transplant for cancer may be more likely to die of treatment-related complications if they live in...
Effect of Angiotensin II Inhibition on Response to Immunotherapy
Researchers have found that a class of commonly used heart drugs may also improve patients’ responses to PD-L1 inhibitors, according to preliminary findings presented by Strauss et al at the 32th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (Abstract 7). Angiotensin...
Sexual Health Often Overlooked in Cancer Survivorship Care
A new study points to a need for oncologists to ask their patients about sexual health after chemotherapy, radiation, and other cancer treatments. In a survey of nearly 400 cancer survivors, 87% said they experienced sexual side effects, but most also said their oncologist had not formally asked...
Geographic Access to Radiotherapy Facilities in the United States
The number of radiation therapy facilities in the United States has grown by 17% over the past 15 years, according to a new study presented by Maroongroge et al at the 2020 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 203). However, this growth has disproportionately...
Study Finds Further Efforts Needed for Inclusion of Underrepresented Populations in Radiotherapy Clinical Trials
A new study finds that the racial composition of clinical trials involving radiation therapy does not match that of the U.S. population. Examining trials from the past 23 years, researchers found that roughly 12% of trial participants were Black, which is less than the 13% population composition of ...
SBRT for Multiple Lung Metastases: How Many Treatment Sessions Are Optimal?
Delivering stereotactic body radiation therapy (SBRT, also called stereotactic ablative radiotherapy) in either one or four treatment sessions led to similar outcomes in patients with up to three lung metastases in the randomized SAFRON II trial. The study, reported by Shankar Siva, PhD, and...
Survey Shows Many Patients With Cancer Willing to Take Part in Clinical Trials Despite Coronavirus
Patient Power, a patient-driven cancer news organization, reported that a majority of patients with cancer still want to participate in clinical trials despite the COVID-19 pandemic, according to a recent survey of 1,485 patients. The Patient Power COVID-19 Cancer Trial Survey, the second Patient...
SHP2 Inhibition May Counter Resistance Mechanisms in Lung Cancer
Recent preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, an affiliate of Navire Pharma, found that the novel SHP2 inhibitor IACS-13909 may be able to overcome therapeutic resistance mechanisms in non–small cell lung cancer (NSCLC). The data, which...
Becoming Acquainted With Cancer
Editor’s Note: The ASCO Post learned of the death of Patrick Beauregard due to colorectal cancer on September 6, 2020. Just weeks after my wedding in late summer of 2017, I had a sudden bout of abdominal pain so severe that it sent me to the emergency room. I was just 29 years old and in great...
Remembering Patrick H. Beauregard: ‘Selfless in His Efforts to Raise Awareness’ of Colorectal Cancer in Young Adults
The editors of The ASCO Post are sad to report the death of Patrick H. Beauregard on September 6, 2020. The cause was colorectal cancer. Diagnosed with stage IV disease in 2017 at the age of 29, Mr. Beauregard dedicated the last 3 years of his life to raising awareness of colorectal cancer in...
Early-Career ASCO Member and Breast Medical Oncologist, Tomas Lyons, MB BCh, BAO, MRCPI, Dies at 38
Tomas Lyons, MB BCh, BAO, MRCPI, a medical oncologist at the Evelyn H. Lauder Breast Center Memorial Sloan Kettering Cancer Center in New York, died suddenly on September 29 at the age of 38. During his career at Memorial Sloan Kettering (MSK), he was a celebrated collaborator on multidisciplinary ...
